Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20469229 | 0.88 | CACNA1G (0.41) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL6812673 | 0.86 | CACNA1G (0.42) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL1928525 | 0.85 | HDAC3 (0.45) | HTR2CSLC6A4PAX8 | |
| SCHEMBL20456732 | 0.83 | CACNA1G (0.38) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL1928811 | 0.81 | NOX1 (0.39) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL1927572 | 0.78 | HDAC1 (0.45) | CACNA1BCACNA1CCKS1BSKP1SKP2 | |
| SCHEMBL2477578 | 0.77 | CCNE2 (0.39) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL27564497 | 0.77 | PAX8 (0.46) | PAX8GSTO1CKS1BSKP1SKP2 | |
| SCHEMBL2843052 | 0.76 | HTR2C (0.46) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL1928104 | 0.76 | IDO1 (0.49) | CKS1BSKP1SKP2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1228760-B1 | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | IPSEN PHARMA (FR) | 2011-08-31 | — | — | EP | claimed |
| US-7566734-B2 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-07-28 | — | — | US | claimed |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | LASSAUNIERE PIERRE-ETIENNE CHA | 2008-06-19 | — | — | US | claimed |
| US-7291641-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-11-06 | — | — | US | claimed |
| EP-1305294-B1 | IMIDAZOLYL DERIVATIVES | SOD CONSEILS RECH APPLIC (FR) | 2007-04-25 | — | — | EP | claimed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | claimed |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-02-17 | — | — | US | claimed |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-08 | — | — | US | claimed |
| EP-1228760-A2 | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-08-07 | — | — | EP | claimed |
| EP-1223933-A2 | 5-MEMBERED HETEROCYCLE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-07-24 | — | — | EP | claimed |
| WO-2001026656-A2 | 5-MEMBERED HETEROCYCLE DERIVATIVES AND USE THEREOF AS MONOAMINE OXIDASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-04-19 | — | — | WO | claimed |
| EP-1589007-B1 | 5-membered heterocycle derivatives, production thereof and their use as medicaments | IPSEN PHARMA (FR) | 2015-06-03 | — | — | EP | disclosed |
| US-8288560-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2012-10-16 | — | — | US | disclosed |
| EP-1228760-B1 | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | IPSEN PHARMA (FR) | 2011-08-31 | — | — | EP | disclosed |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | IPSEN PHARMA S.A.S. (FR) | 2011-07-14 | — | — | US | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20070021390-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SCRAS | 2007-01-25 | — | — | US | disclosed |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-02-17 | — | — | US | disclosed |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-08 | — | — | US | disclosed |
| EP-1228760-A2 | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021390-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | PARK7, SNCA, COMT | HTR2C 290/4885SLC6A4 1338/4885CACNA1G 4498/4885 |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, OPRK1 | HTR2C 308/4885SLC6A4 1978/4885CACNA1G 1370/4885 |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OPRK1, HCN1, P2RX7 | HTR2C 169/4885SLC6A4 997/4885CACNA1G 865/4885 |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | OXER1, OPRL1, CHRNA7 | HTR2C 407/4885SLC6A4 1420/4885CACNA1G 1094/4885 |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, P2RX7 | HTR2C 518/4885SLC6A4 1103/4885CACNA1G 965/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | HTR2C 426/4885SLC6A4 478/4885CACNA1G 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.